Recent pharmacological study using santacruzamate A, in combination with other HDAC inhibitors, such as HDAC1 inhibitor, tacedinaline, HDAC1/2 common inhibitor, romidepsin (FK228) and global HDAC inhibitor, vorinostat (SAHA), to treat hepatocellular carcinoma (HCC) was reported [56]. Here, HDAC1 is linked to hepatocellular carcinoma.